3-(Cyclopenten-1-yl)-benzyl-or...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S462000, C549S330000, C549S467000

Reexamination Certificate

active

10531587

ABSTRACT:
The invention provides compounds of the formula:wherein (a) is a single or double bond; W is CH, CH2, CHCH3, CCH3, C(CH3)2, C(CH2)2or C(CH2)3, provided that when (a) is a double bond, then W is CH or CCH3, and when (a) is a single bond, then W is CH2, CHCH3, C(CH3)2, C(CH2)2or C(CH2)3; X is CH or N; and Y is H or F, and salts, hydrates, tautomers, pure enantiomers, and enantiomeric mixtures; and a method of treating schizophrenia comprising administering same.

REFERENCES:
patent: 6417222 (2002-07-01), Vacher et al.
patent: 05-125024 (1993-05-01), None
patent: 99/51575 (1999-10-01), None
patent: 99/58527 (1999-11-01), None
patent: 00/58282 (2000-10-01), None
Yanusaga, T. et al., “Preparation of(hetero)aryloxyalkylamine derivatives having selective affinity to serotonin(5-HT 1A)receptors”, Chemical Abstracts, Oct. 25, 1993, Abstract No. 180657, vol. 119, No. 17, Chemical Abstracts Service, Columbus, OH, USA, abstract of JP05-125024.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

3-(Cyclopenten-1-yl)-benzyl-or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3-(Cyclopenten-1-yl)-benzyl-or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-(Cyclopenten-1-yl)-benzyl-or... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3789000

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.